Zymergen Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by FLATLEY JAY T, was filed 19 Nov 2021.
Zymergen Inc.: what insiders have been doing
This page follows insider dealings at Zymergen Inc. as filed with SEC (Form 4), a company from the Chemicals & Materials sector. Zymergen Inc. has had no insider filing for more than a year; the last one goes back to 21 October 2022.
Looking back to 2021, when coverage begins, insiders filed 1 purchase and 26 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
- 26,614,219 sharesCommon StockSEC:0000899243-22-033957:0
- 40,000 sharesCommon StockSEC:0001645842-22-000130:1
- 40,000 sharesCommon StockSEC:0001645842-22-000130:2
- 4,917,734 sharesCommon StockSEC:0001645842-22-000136:1
- 50,000 sharesCommon StockSEC:0001645842-22-000147:0
- 119,119 sharesCommon StockSEC:0001645842-22-000144:0
- 79,697 sharesCommon StockSEC:0001645842-22-000142:0
- 2,551,685 sharesCommon StockSEC:0001645842-22-000130:0
- 144,789 sharesCommon StockSEC:0001645842-22-000149:0
- 2,448,901 sharesCommon StockSEC:0001645842-22-000136:0
- 462,241 sharesCommon StockSEC:0001645842-22-000131:0
- 50,000 sharesCommon StockSEC:0001645842-22-000140:0
- 3,786 shares@ US$2.79928.3% of flowCommon StockSEC:0001645842-22-000128:0
- 3,410 shares@ US$2.2125.8% of flowCommon StockSEC:0001645842-22-000124:0
- 3,928 shares@ US$2.216.7% of flowCommon StockSEC:0001645842-22-000126:0
- 3,268 shares@ US$2.213.3% of flowCommon StockSEC:0001645842-22-000122:0
- 15,365 shares@ US$2.274426.9% of flowCommon StockSEC:0001645842-22-000120:0
- 5,435 shares@ US$3.919.2% of flowCommon StockSEC:0001645842-22-000118:0
- 8,320 shares0Common StockSEC:0001645842-22-000116:0
- 3,094 shares@ US$2.612527.1% of flowCommon StockSEC:0001645842-22-000107:0
- 2,966 shares@ US$2.61253.4% of flowCommon StockSEC:0001645842-22-000109:0
- 2,797 shares@ US$1.32231.6% of flowCommon StockSEC:0001645842-22-000104:0
- 2,924 shares@ US$1.322312.8% of flowCommon StockSEC:0001645842-22-000102:0
- 50,000 shares0Common StockSEC:0001645842-22-000096:0
- 50,000 shares0Common StockSEC:0001645842-22-000090:0
25 of 65 declarations
About Zymergen Inc.
Zymergen Inc. was a U.S.-based industrial biotechnology company founded in 2013 by Joshua Hoffman, Zach Serber, and Jed Dean. Its headquarters were in Emeryville, California, United States, and it was listed on the U.S. NASDAQ market. For European investors, Zymergen sat at the intersection of synthetic biology, advanced materials, and specialty chemicals, with a business model focused on engineering microorganisms to produce molecules and materials traditionally derived from petrochemicals. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Zymergen?utm_source=openai))
From a historical perspective, Zymergen raised substantial capital to build a platform combining genomics, automation, and machine learning. The company’s long-term thesis was to create industrial inputs that could be safer, more sustainable, and potentially cheaper than conventional manufacturing routes. In market terms, Zymergen became known as an ambitious “deep tech” industrial biotech story, attracting attention for its attempt to replace petroleum-based materials with biologically produced alternatives. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Zymergen?utm_source=openai))
Read moreShow less
Operationally, the company’s core activity centered on R&D for engineered microbes and bio-manufacturing processes. Its product and technology offering was geared toward materials and chemical intermediates for consumer electronics and other industrial applications. The best-known commercial product was Hyaline, a bio-manufactured polyimide film described as transparent and flexible, designed for certain electronic-use cases. Zymergen also communicated about broader potential applications across consumer goods and pharmaceuticals, reflecting the platform nature of its technology stack. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Zymergen?utm_source=openai))
In competitive terms, Zymergen tried to differentiate itself through a technology-intensive, data-driven approach to industrial biology. However, execution proved difficult. SEC-related materials and restructuring disclosures indicate that the company faced major scale-up, commercialization, and industrial validation challenges, which undermined its revenue generation and ultimately its public-market narrative. That combination of high R&D intensity and weak near-term monetization made the equity story highly speculative. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Zymergen?utm_source=openai))
Recent developments are decisive. In 2022, Ginkgo Bioworks announced an acquisition involving Zymergen, and SEC filings show that Ginkgo completed the acquisition of substantially all of Zymergen’s assets on January 18, 2024. Zymergen’s plan of liquidation was then confirmed by the bankruptcy court on February 5, 2024. As a result, Zymergen no longer functions as an independent public company. For investors, that means the name is now primarily relevant as a completed restructuring/bankruptcy case rather than an ongoing listed equity story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1830214/000162828024022229/dna-20240331.htm?utm_source=openai))
